Adjuvants designed for veterinary and human vaccines

被引:313
作者
Aucouturier, J
Dupuis, L
Ganne, V
机构
[1] Seppic 75, 75321 Paris Cedex 07, Quai D'orsay
关键词
emulsions; nanoparticles; adjuvants;
D O I
10.1016/S0264-410X(00)00498-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adjuvants play an important role in the efficacy of vaccines as the antigens become more and more purified. Indeed recombinant proteins or synthetic peptides are safer than crude inactivated micro-organism, but less immunogenic. This can be balanced by specific adjuvants. But there is no universal adjuvants and their action is not vet clear and rely on different mechanisms. Then, they must be adapted according to several criteria, like the target species, the antigens. the type of immune response, the route of inoculation, or the duration of immunity. For this purpose different type of emulsions have been developed. Water in oil (W/O) emulsions induce a strong and long term immune response. Those based on mineral oils are known to be very efficient but can sometimes induce local reactions with reactive antigens. Non mineral oils are well tolerated but less efficient with poor immunogens. Multiphasic (W/O/W) emulsions can induce short and long term immune responses with various antigens and oil in water (OW) emulsions are well tolerated and induce a short term immune response. New generation of adjuvants are based on a new concept called 'immunosol' and stem from the association of nanoparticles with a new immunostimulant. They can be used when emulsions are not suitable to obtain a good balance between safety and immunogenicity. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2666 / 2672
页数:7
相关论文
共 50 条
  • [1] Aguado Teresa, 1999, Vaccine, V17, P2321
  • [2] Aikawa K, 1998, Pharm Dev Technol, V3, P461, DOI 10.3109/10837459809028627
  • [3] ALTMAN A, 1989, ADV VET SCI COMP MED, V33, P301
  • [4] [Anonymous], 2000, DRUGS PHARM SCI
  • [5] AUCOUTURIER J, 2000, P 20 WORLD POULTR C
  • [6] AUCOUTURIER J, 1999, P PPRS AUJ JUN 21 24
  • [7] ADJUVANTS - CURRENT STATUS, CLINICAL PERSPECTIVES AND FUTURE-PROSPECTS (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 174-178, 1993)
    AUDIBERT, FM
    LISE, LD
    [J]. IMMUNOLOGY TODAY, 1993, 14 (06): : 281 - 284
  • [8] BAHNEMANN HG, 1987, BOL CTR PANAM FIEBRE, V53, P25
  • [9] International bank for foot-and-mouth disease vaccine: Assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants
    Barnett, PV
    Pullen, L
    Williams, L
    Doel, TR
    [J]. VACCINE, 1996, 14 (13) : 1187 - 1198
  • [10] Becher P, 1965, EMULSION THEORY PRAC